The A300E mAb was initially developed against the disintegrin–EGF-like domain of human ADAM17 [189]; when conjugated to doxorubicin or Pseudomonas exotoxin, it induces in vitro death of breast cancer cells in an ADAM17-dependent manner [191]. This evidence concerns the gene ADAM17 and breast carcinoma.